Advertisement

Topics

Kandi Technologies Clarifies Comments Made During Today's Conference Call

20:00 EDT 9 Aug 2015 | Globe Newswire

JINHUA, China, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Kandi Technologies Group, Inc. (the "Company" or "Kandi") (NASDAQ:KNDI), today announced during Kandi Technologies' conference call this morning to discuss second quarter 2015 results, a mistranslation of the chief executive officer Mr. Hu Xiaoming's response to a question has created a misunderstanding regarding the Company's outlook for EV product sales. Mr. Hu noted that China's government expects the total number of cars on the road in China by 2020 could reach 200 million, and that EV products could make up 2.5% to 3% of that total. Mr. Hu's comment was not in reference to Kandi's share of the market.

During the call, Mr. Hu did reiterate the Company's longer-term objective of 400,000 EV car sales in 2020.

About Kandi Technologies Group, Inc.

Kandi Technologies Group, Inc. (KNDI), headquartered in Jinhua, Zhejiang Province, is engaged in the research and development, manufacturing and sales of various vehicle products. Kandi has established itself as one of China's leading manufacturers of pure electric vehicle ("EV") products (through its joint venture), EV parts and off-road vehicles. More information can be viewed at the Company's corporate website at http://www.kandivehicle.com.

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

CONTACT: Company Contact:
         
         Ms. Kewa Luo
         Kandi Technologies Group, Inc.
         Phone: 1-212-551-3610
         Email: IR@kandigroup.com
         
         IR Contact:
         
         The Piacente Group
         Phone: 1-212-481-2050
         Email: kandi@tpg-ir.com
NEXT ARTICLE

More From BioPortfolio on "Kandi Technologies Clarifies Comments Made During Today's Conference Call"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...